reports
Cantourage Group SE: 1 director
A director at Cantourage Group SE sold 20,144 shares at 7.004EUR and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
- ABGSC Capital Goods Research
- Karl Bokvist
GameStop Announces First Quarter Preliminary Results
GameStop Announces First Quarter Preliminary Results GRAPEVINE, Texas, May 17, 2024 (GLOBE NEWSWIRE) -- GameStop Corp. (NYSE: GME) (“GameStop” or the “Company”) today announced certain preliminary unaudited financial information for the first quarter ended May 4, 2024. On a preliminary basis for the 13-weeks ended May 4, 2024 compared to the 13-weeks ended April 29, 2023: Net sales are expected to be in the range of $0.872 billion to $0.892 billion compared to $1.237 billion in the prior year fiscal quarter.Selling, general and administrative (“SG&A") expenses are expected to be in ...
Hardman & Co Research on Volta Finance Limited: Putting the discount i...
Hardman & Co Research Hardman & Co Research on Volta Finance Limited: Putting the discount into perspective 17-May-2024 / 12:15 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research | Closed End Investments Volta Finance Limited (VTAS) | Putting the discount into perspective Volta’s share price discount to NAV (26%) is now back to the levels seen in the early stages of the pandemic. This appears anomalous with 6.3% total shareholder return in 1Q’24, the annualised cashflows in excess of 20%, the consensus outlook, as well as the...
Gamma Communications: 1 director
A director at Gamma Communications sold 5,000 shares at 1,451p and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
ChemoMetec A S: 2 directors
A director at ChemoMetec A S bought 1,427 shares at 348.960DKK and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Sjm Holdings Limited: 1 director
A director at Sjm Holdings Limited bought 8,827,000 shares at 2.997HKD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Telix Files Registration Statement for Proposed Initial Public Offerin...
Telix Files Registration Statement for Proposed Initial Public Offering in the United States MELBOURNE, Australia, May 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has filed a registration statement on Form F-1 (Registration Statement) with the United States (U.S.) Securities and Exchange Commission (SEC) today (U.S. time) relating to a proposed initial public offering (Offering) of its American Depository Shares (ADSs), representing the Company’s ordinary shares, in the U.S. Telix has applied to list the ADSs on the Nas...
Brenntag SE: 1 director
A director at Brenntag SE bought 700 shares at 71.277EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
DSV, 1110 - MAJOR SHAREHOLDER ANNOUNCEMENT
DSV, 1110 - MAJOR SHAREHOLDER ANNOUNCEMENT Company Announcement No. 1110 Pursuant to section 30 of the Danish Capital Markets Act it is announced that BlackRock, Inc. has informed DSV A/S that the total shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2) of the Danish Capital Markets Act of DSV A/S held by BlackRock, Inc. as of 14 May 2024 correspond to below 5% of the entire share capital and below 5% of the voting rights of DSV A/S. ContactsInvestor Relations: Sebastian Rosborg, tel. , Yours sincerely,DSV ...
Lonking Holdings Ltd: 1 director
A director at Lonking Holdings Ltd sold 1,714,000 shares at 1.713HKD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Alliance Entertainment Holding Corp: 2 directors
Two Directors at Alliance Entertainment Holding Corp bought 23,000 shares at between 2.540USD and 2.550USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's...
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sc...
RADNOR, Pa.--(BUSINESS WIRE)-- , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced completion of enrollment in the global Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures associated with tuberous sclerosis complex (TSC) in children and adults. “We are pleased to announce we have completed enrollment in our pivotal Phase 3 trial in tuberous sclerosis complex,” said Alex Aimetti, Ph.D., Chief Scientific Officer at Marinus Pharmaceuticals. “The TrustTSC study enrolled hi...
Keskisuomalainen Oyj:n johtohenkilöiden liiketoimet - Kangaskorpi
Keskisuomalainen Oyj:n johtohenkilöiden liiketoimet - Kangaskorpi Keskisuomalainen Oyj, johtohenkilöiden liiketoimet, pörssitiedote 17.5.2024 klo 14.00 Keskisuomalainen Oyj - Johdon liiketoimet____________________________________________IlmoitusvelvollinenNimi: Vesa KangaskorpiAsema: ToimitusjohtajaLiikkeeseenlaskija: Keskisuomalainen OyjLEI: 743700J7NHT5OLSJ3B78Ilmoituksen luonne: ENSIMMÄINEN ILMOITUSViitenumero: 63169/4/4____________________________________________Liiketoimen päivämäärä: 2024-05-15Kauppapaikka: NASDAQ HELSINKI LTD (XHEL)Instrumenttityyppi: OSAKEISIN: FI0009007546Liiketoi...
Village Farms International Applauds Historic Move Toward U.S. Marijua...
Village Farms International Applauds Historic Move Toward U.S. Marijuana Rescheduling VANCOUVER, British Columbia and ORLANDO, Fla., May 17, 2024 (GLOBE NEWSWIRE) -- Village Farms International, Inc. (“Village Farms”) (NASDAQ: VFF) applauds the U.S. Department of Justice’s historic decision to pursue federal rescheduling of marijuana for medical purposes to Schedule III from Schedule I under the Controlled Substances Act (CSA) (the “Rescheduling Proposal”). The Rescheduling Proposal starts a 60-day period for public comment. “We are encouraged by this continued regulatory progress and ar...
Autolus Therapeutics Reports First Quarter 2024 Financial Results and ...
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHATwo patients enrolled in Phase 1 Systemic Lupus Erythematosus (SLE) trial; study on track for initial data end of 2024Market Authorization Application (MAA) for obe-cel in r/r adult ALL accepted by European Medicines Agency (EMA)Conference call to be held today at 08:30 am EDT/13:30 pm BST: conference call participants should pre-register using the link at the bottom of this press ...
Virtu Financial Congratulates Michelle Hosea, Recipient of the Rising ...
Virtu Financial Congratulates Michelle Hosea, Recipient of the Rising Star Award at Women in Finance Asia Awards NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Virtu Financial, Inc. (Nasdaq:VIRT), a leading provider of global, multi-asset financial services that delivers liquidity and innovative, transparent products across the complete investment cycle to the global markets, is pleased to congratulate Michelle Hosea, Quantitative Strategist, on her Women in Finance Asia 2024 Rising Star Award. In Michelle’s three years at Virtu, she has quickly taken a leadership role on the quantitative ...
Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company...
Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that management will host 1x1 meetings with investors during the A.G.P. Virtual Healthcare Company Showcase, which is being held May 21, 2024. For more information, or to register: . About Psyence Biomed Psyence Biomedical Ltd., a corporation organized under the laws of Ontario, Canada, is the world’s first life science biotechnology company traded on The Nasdaq Stock Market LLC...
JOYY to Announce First Quarter 2024 Financial Results on May 28, 2024
JOYY to Announce First Quarter 2024 Financial Results on May 28, 2024 SINGAPORE, May 17, 2024 (GLOBE NEWSWIRE) -- JOYY Inc. (NASDAQ: YY) (“JOYY” or the “Company”), a global technology company, today announced that it plans to release its first quarter 2024 financial results after the U.S. market closes on May 28, 2024. The Company’s management will host an earnings conference call at 9:00 PM U.S. Eastern Time on Tuesday, May 28, 2024 (9:00 AM Singapore/Hong Kong Time on Wednesday, May 29, 2024). Details for the conference call are as follows: Event Title:JOYY Inc. First Quarter 2024 E...
Chemomab Therapeutics to Participate in Upcoming Scientific Conference...
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced upcoming scientific presentations at the Gordon Research Conference on Chemotactic Cytokines and at EASL 2024, the Annual Congress of the European Association for the Study of the Liver. The presentations cover a range of topics, from new preclinical studies further elucid...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.